Dapivirine
- Generic Name
- Dapivirine
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19N5
- CAS Number
- 244767-67-7
- Unique Ingredient Identifier
- TCN4MG2VXS
- Background
Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.
Long-Acting HIV Therapies Show Promise Amid Policy Challenges: IDWeek 2024 Highlights
• Lenacapavir, a twice-yearly injectable HIV prevention drug, emerges as a promising option for cisgender women and high-risk populations, with Gilead planning low-cost access in resource-limited regions.
• Long-acting injectable antiretroviral therapy demonstrates success in children and adolescents, with patients maintaining viral suppression and preferring it over daily oral medications.
• Tennessee's rejection of $6.2M CDC funding for HIV prevention raises concerns about healthcare disparities and potential increased transmission rates in high-risk populations.
Gilead's Lenacapavir Shows Promise in HIV Prevention and Treatment
• Gilead's twice-yearly injectable lenacapavir reduced HIV infections by 96% in a Phase 3 trial, demonstrating superiority to daily oral Truvada for PrEP.
• The PURPOSE 2 trial included cisgender men, transgender individuals, and gender non-binary people, showing broad efficacy across diverse populations.
• Gilead plans to begin regulatory filings for lenacapavir for PrEP by the end of 2024, with potential launch in 2025, prioritizing access in high-incidence, resource-limited countries.
• A Phase 2 trial of once-weekly oral islatravir and lenacapavir maintained viral suppression in adults with HIV, paving the way for Phase 3 trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath